Friday, March 24, 2023
No Result
View All Result
  • বাংলা সংস্করণ
Shomporko
Advertisement
  • Home
  • News
    • Daily News
    • Feature
    • Sports
  • CANADA
    • Canada Daily
    • Community News
    • Canada Politics
    • Canada Economy
    • Canada Health
  • Global
  • Bangladesh
  • Interview
  • Article
    • Analytical
  • LITERATURE
    • Story
    • Poem
  • Opinion
    • Columnists
  • More
    • Food & Beverage
    • HISTORY
    • Kids Page
    • Travel
    • HOME DECOR
    • Video
    • Social Media
    • Festival
  • Home
  • News
    • Daily News
    • Feature
    • Sports
  • CANADA
    • Canada Daily
    • Community News
    • Canada Politics
    • Canada Economy
    • Canada Health
  • Global
  • Bangladesh
  • Interview
  • Article
    • Analytical
  • LITERATURE
    • Story
    • Poem
  • Opinion
    • Columnists
  • More
    • Food & Beverage
    • HISTORY
    • Kids Page
    • Travel
    • HOME DECOR
    • Video
    • Social Media
    • Festival
No Result
View All Result
Shomporko
No Result
View All Result
Home Health

Moderna’s coronavirus vaccine is 94.5 percent effective, according to company data

by Shomporko
November 17, 2020
in Health
0
Moderna’s coronavirus vaccine is 94.5 percent effective, according to company data
0
SHARES
32
VIEWS
Share on FacebookShare on Twitter

For the second time this month, there’s promising news from a COVID-19 vaccine candidate: Moderna said Monday its shots provide strong protection, a dash of hope against the grim backdrop of coronavirus surges in the U.S. and around the world.

Moderna said its vaccine appears to be 94.5% effective, according to preliminary data from the company’s still ongoing study. A week ago, competitor Pfizer Inc. announced its own COVID-19 vaccine appeared similarly effective — news that puts both companies on track to seek permission within weeks for emergency use in the U.S.

Dr. Stephen Hoge, Moderna’s president, welcomed the “really important milestone” but said having similar results from two different companies is what’s most reassuring.

“That should give us all hope that actually a vaccine is going to be able to stop this pandemic and hopefully get us back to our lives,” Hoge told The Associated Press.

“It won’t be Moderna alone that solves this problem. It’s going to require many vaccines” to meet the global demand, he added.

A vaccine can’t come fast enough, as virus cases topped 11 million in the U.S. over the weekend — 1 million of them recorded in just the past week. The pandemic has killed more than 1.3 million people worldwide, more than 245,000 of them in the U.S.

Still, if the Food and Drug Administration allows emergency use of Moderna’s or Pfizer’s candidates, there will be limited, rationed supplies before the end of the year. Both require people to get two shots, several weeks apart. Moderna expects to have about 20 million doses, earmarked for the U.S., by the end of 2020. Pfizer and its German partner BioNTech expect to have about 50 million doses globally by year’s end.

Moderna’s vaccine, created with the National Institutes of Health, is being studied in 30,000 volunteers who received either the real vaccination or a dummy shot. On Sunday, an independent monitoring board broke the code to examine 95 infections that were recorded starting two weeks after volunteers’ second dose — and discovered all but five illnesses occurred in participants who got the placebo.

The study is continuing, and Moderna acknowledged the protection rate might change as more COVID-19 infections are detected and added to the calculations. Also, it’s too soon to know how long protection lasts. Both cautions apply to Pfizer’s vaccine as well.

But Moderna’s independent monitors reported some additional, promising tidbits: All 11 severe COVID-19 cases were among placebo recipients, and there were no significant safety concerns.

Moderna shares rocketed higher on the announcement and appeared to be headed for an all-time high Monday. The Cambridge, Massachusetts, company’s vaccine is among 11 candidates in late-stage testing around the world, four of them in huge studies in the U.S.

Both Moderna’s shots and the Pfizer-BioNTech candidate are so-called mRNA vaccines, a brand-new technology. They aren’t made with the coronavirus itself, meaning there’s no chance anyone could catch it from the shots. Instead, the vaccine contains a piece of genetic code that trains the immune system to recognize the spiked protein on the surface of the virus.

The strong results were a surprise. Scientists have warned for months that any COVID-19 shot may be only as good as flu vaccines, which are about 50% effective.

Photo credit: AP / Hans Pennink

News source: The Associated Press

Tags: Health#Moderna's coronavirus vaccine is 94.5 percent effective
Previous Post

Three regions move to Ontario's COVID-19 'red zone' restrictions today

Next Post

Bangladesh receives $1.22 billion remittances in 15 days

Shomporko

Related Posts

Nearly 30 per cent of kids ages 5-11 in Toronto have received 1st dose of COVID-19 vaccine
Canada Daily

Nearly 30 per cent of kids ages 5-11 in Toronto have received 1st dose of COVID-19 vaccine

December 10, 2021
COVID-19: Where the major parties stand on vaccine passports
Canada Health

COVID-19: Where the major parties stand on vaccine passports

September 3, 2021
Ontario reports largest increase in COVID-19 cases since early June, 1 additional death
Dailynews

Ontario reports largest increase in COVID-19 cases since early June, 1 additional death

August 21, 2021
Faculty groups at McGill University call for COVID-19 vaccine mandate
Canada Daily

Faculty groups at McGill University call for COVID-19 vaccine mandate

August 20, 2021
Facebook says it’s ‘not the reason’ U.S. is failing to meet COVID-19 vaccine goals
Global

Facebook says it’s ‘not the reason’ U.S. is failing to meet COVID-19 vaccine goals

July 18, 2021
WHO still struggling to manage the pandemic response
Global

WHO still struggling to manage the pandemic response

March 12, 2021
Next Post
Bangladesh receives $1.22 billion remittances in 15 days

Bangladesh receives $1.22 billion remittances in 15 days

Logo

Disclaimer:

The editorial team is not responsible for the content of the writing.

Publisher and Editor
Sonia Hoque

General Manager

Rewrite-Man

Reporter

Graphics
Mozammel Sarkar

Address:

Shomporko Magazine

59 Byng ave
Scarborough,
Ontario
M1L3N8

Phone :647-686-5432

 

Email: 
shomporko.magazine@gmail.com
2537765 Ontario Ltd

© 2020 Shomporko – Magazine Develop by RMITtech

No Result
View All Result
  • Home
  • NEWS
    • Daily News
    • Feature
    • Global
    • Politics
    • Sports
  • CANADA
    • Canada Daily
    • Community News
    • Canada Politics
    • Canada Economy
    • Canada Immigration
    • Canada Education
    • Canada Health
    • Canada Opinion
  • GLOBAL
  • INTERVIEW
  • ARTICLE
    • Analytical
  • LITERATURE
    • Story
    • Poem
  • OPINION
    • Opinion
    • Columnists
    • Legal Advice
  • ARTS
    • Home Decor
    • Sports
  • LIVING
    • Health
    • Food
    • Travel
    • HISTORY
    • Kids Page
  • MORE
    • Video
    • Social Media
    • Festival
  • বাংলা সংস্করণ

© 2019 Shomporko - Magazine Develop by RMITtech.

Translate »